| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
61,556,000 |
| Market
Cap: |
2.22(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$25.77 - $37.83 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. Co.'s products include Trokendi XR and Oxtellar XR, which are the once-daily extended release topiramate and oxcarbazepine products indicated for the treatment of epilepsy; APOKYN, which is a product indicated for the intermittent treatment of hypomobility or off episodes in patients with Parkinson's Disease (PD); XADAGO, which is an once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD; and MYOBLOC, which is a product indicated for the treatment of cervical dystonia and sialorrhea in adults.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
323,308 |
323,308 |
429,813 |
534,316 |
| Total Sell Value |
$11,727,248 |
$11,727,248 |
$15,296,374 |
$19,204,299 |
| Total People Sold |
5 |
5 |
7 |
7 |
| Total Sell Transactions |
8 |
8 |
15 |
32 |
| End Date |
2024-08-25 |
2024-05-24 |
2023-11-24 |
2022-11-24 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Newhall Charles W III |
Director |
– • – |
2024-11-11 |
4 |
S |
$36.24 |
$387,768 |
D/D |
(10,700) |
130,275 |
|
1% |
|
| Newhall Charles W III |
Director |
– • – |
2024-11-11 |
4 |
OE |
$9.13 |
$182,600 |
D/D |
20,000 |
140,975 |
|
- |
|
| Gemayel Georges |
Director |
– • – |
2024-11-08 |
4 |
S |
$36.30 |
$391,568 |
D/D |
(10,787) |
13,315 |
|
1% |
|
| Gemayel Georges |
Director |
– • – |
2024-11-08 |
4 |
OE |
$11.46 |
$123,619 |
D/D |
10,787 |
24,102 |
|
- |
|
| Hudson Frederick M. |
Director |
– • – |
2024-11-08 |
4 |
S |
$36.28 |
$316,434 |
D/D |
(8,722) |
28,395 |
|
1% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2024-11-08 |
4 |
S |
$36.29 |
$4,536,250 |
D/D |
(125,000) |
926,172 |
|
1% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2024-11-08 |
4 |
OE |
$9.13 |
$1,141,250 |
D/D |
125,000 |
1,051,172 |
|
- |
|
| Mottola Frank |
SVP, Quality, GMP, Ops, IT |
• – – |
2024-11-07 |
4 |
S |
$36.98 |
$554,700 |
D/D |
(15,000) |
8,200 |
|
0% |
|
| Mottola Frank |
SVP, Quality, GMP, Ops, IT |
• – – |
2024-11-07 |
4 |
OE |
$9.13 |
$136,950 |
D/D |
15,000 |
23,200 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2024-11-07 |
4 |
S |
$36.68 |
$4,585,000 |
D/D |
(125,000) |
926,172 |
|
0% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2024-11-07 |
4 |
OE |
$9.13 |
$1,141,250 |
D/D |
125,000 |
1,051,172 |
|
- |
|
| Gemayel Georges |
Director |
– • – |
2024-11-07 |
4 |
S |
$36.62 |
$520,480 |
D/D |
(14,213) |
13,315 |
|
0% |
|
| Gemayel Georges |
Director |
– • – |
2024-11-07 |
4 |
OE |
$11.46 |
$162,881 |
D/D |
14,213 |
27,528 |
|
- |
|
| Gemayel Georges |
Director |
– • – |
2024-09-13 |
4 |
S |
$31.33 |
$435,048 |
D/D |
(13,886) |
13,315 |
|
-16% |
|
| Gemayel Georges |
Director |
– • – |
2024-09-13 |
4 |
OE |
$11.46 |
$114,600 |
D/D |
10,000 |
23,315 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2024-09-03 |
4 |
D |
$34.90 |
$350,571 |
D/D |
(10,045) |
926,172 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2024-09-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,000 |
936,217 |
|
- |
|
| Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
• – – |
2024-08-20 |
4 |
D |
$29.57 |
$16,914 |
D/D |
(572) |
9,679 |
|
- |
|
| Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
• – – |
2024-08-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,250 |
10,251 |
|
- |
|
| Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
• – – |
2024-03-21 |
4 |
AS |
$35.31 |
$511,677 |
D/D |
(14,491) |
8,570 |
|
-16% |
|
| Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
• – – |
2024-03-21 |
4 |
OE |
$25.30 |
$366,622 |
D/D |
14,491 |
23,061 |
|
- |
|
| Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
• – – |
2024-03-20 |
4 |
AS |
$35.31 |
$14,124 |
D/D |
(400) |
8,570 |
|
-15% |
|
| Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
• – – |
2024-03-20 |
4 |
OE |
$25.30 |
$10,120 |
D/D |
400 |
8,970 |
|
- |
|
| Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
• – – |
2024-03-19 |
4 |
AS |
$35.31 |
$436,573 |
D/D |
(12,364) |
8,570 |
|
-14% |
|
| Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
• – – |
2024-03-19 |
4 |
OE |
$25.30 |
$312,809 |
D/D |
12,364 |
20,934 |
|
- |
|
362 Records found
|
|
Page 1 of 15 |
|
|
0.12 (0.33%) 
